Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central anxious program, conolidine modulates alternate molecular targets. A Science Advances research discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://bookmarkyourpage.com/story6299085/conolidin-to-replace-traditional-painkillers-fundamentals-explained